|
|
|
市場調查報告書
美國RNAi市場之現況及未來展望
The Exploding RNAi Market & Future Direction Translating the Genome into a Large Market by 2009
|
美國RNAi市場之現況及未來展望 是由出版商Fuji-Keizai U.S.A., Inc.在2006年02月所出版的。
這份英文市場調查報告書包含130 PAGES 價格從美金1295起跳。
1998年自然發生的RNA干預效果被2位科學家發現以來,RNA干預成為在過去10年內是生物學研究領域中最受期待的新技術。若說RNA干預將成為超越PCR的頂尖技術,那可是一點也不為過。
專門於資訊科技、生物科技、奈米科技3大領域市場調查、顧問服務的美國市調公司Fuji-Keizai U.S.A., Inc. (總公司:New York City),針對美國的RANi干預市場的現況及未來展望進行調查分析及預測,並出版報告書 "The Exploding RNAi Market & Future Direction Translating the Genome into a Large Market by 2009"。
本報告書內容包括:RNAi的基礎研究、藥物發現、藥品開發、治療藥用途、各家企業競爭的市場現況及未來發展方向與展望等。內容綱要摘記如下:
※本報告書可購買日文版。購買時,請選擇本頁下方價格訊息處的"Japanese Version" 。
實施概要
第1章 美國RNAi市場及商業模式
- RNA干預概要
- 寫在前面
- 雙股RNA(dsRNA)
- 短股干預(siRNA或是short interfering RNA)
- 短髮夾結構RNA(shRNA)
- DNA-directed RNAi (ddRNAi)
- 微RNA(miRNA)
- 今日美國的RNAi市場及主要顧客應用
- 現今的美國RNAi市場
- 作為傳統藥物發現用工具的NAi
- 藥品R&D及RNAi
- 作為基礎研究工具的RNAi
- 作為治療藥的RNAi
- 市場勢力圖
- 大型企業的市場勢力圖
- 主要企業、焦點市場、產品策略
- 調查結果及分析
- 市場領導企業
- 未來可望實現的應用、趨勢
- 優勢技術:整體介紹
- 最佳的商業模式、產品發展策略
第2章 合作及M&A活動
- RNAi合作及M&A活動分析:2003年至2005年
- RNAi合作及M&A 2003年至2005年
- 法律關係:智慧財產權及規範組織的認可
- 研究人員的發現事項: 應矚目的未來R&D企業
- 值得矚目的RNAi科技企業
- 開始RNAi相關研究的大型製藥企業
第3章 市場評價及趨勢
- 美國RNA干預市場規模: 2004年至2009年
- 美國RNAi市場: 市場區隔別
- RNAi市場: 構成應用領域的市場區隔
- 「RNAi的基礎研究」市場區隔
- 「利用RNAi的藥物發現」市場區隔
- 「利用RNAi的藥品開發」市場區隔
- 「RNAi治療藥」市場區隔
- RNAi應用・市場區隔的市場占有率:2005年至2009年
- RNAi市場: 主要疾病市場區隔別
- 癌症
- 傳染病
- 代謝性疾病
- 眼部疾病
- 中樞神經(CNS)疾病
- 呼吸器官疾病
- 炎症
- 骨頭疾病
- 血液疾病
- 心臟血管疾病
- 診斷、皮膚科及其他
- 主要疾病市場區隔的市場占有率(%):2005年 & 2009年
- RNAi市場 - 產品市場區隔別
- RNAi試藥及相關服務
- RNAi給藥工具&設備
- 檢驗系統
- 細胞株&相關產品
- 藥物發現技術、服務&藥品
- 全基因RNAi HT/HC掃描工具
- RNAi產品市場區隔
- 主要趨勢/今後的方向
- 開始進入RNAi領域的大型製藥企業
- 因應開發不成功效果之方式的進化
- microRNA的功能幾乎不為人知
- 以RNAi為基礎的藥品直接投遞
- RNAi藥品的全身投遞
- RNAi的未來發展方向
第4章 RNAi企業的活動及策略
- 共同調查項目
- 聯絡資訊
- 財務資訊
- 資金提供者資訊
- A. 企業介紹
- B. 合作、M&A
- C. 其他調查結果(專利、資金投入)
- RNAi的基礎研究(5家)
- 藥物發現領域中被利用的RNAi(5家)
- RNAi藥品及治療法發展(11家)
第5章 調查結果及建議
- 調查結果及關鍵趨勢回顧
- 刺激新商機的建議
- 現況:RNAi利用者為了R&D工作迫切需要的產品
- 未來市場發展預測
第6章 附錄
圖表
Abstract
Executive Summary
Since its discovery in 1998 by two scientists, the naturally occurring RNA
interference effect has been hailed as the hottest technical breakthrough in
biological research in the last decade. It may even surpass PCR as a top
technology. RNA interference allows scientists to silence the expression or
effect of a gene being studied. Known simply as RNAi, this field has rapidly
emerged as a fast growing new market. Much like the go-go times of 1999, VC
investments in 2003-2005 have produced a growing new crop of interesting RNAi
companies.
This report assesses this emerging commercial market and maps the players on
the market landscape. The initial companies produced reagents and kits for the
biological research reagents market to support basic and applied research in
academia, government and industry. A number of companies decided to take the
long road to develop therapeutics. Others have developed drug delivery
approaches for emerging RNAi therapeutics.
Some companies have decided to focus on offering RNAi based target validation
products or services for drug discovery or to companies like big pharmas or
biotech drug discovery firms. Other companies are trying other approaches such
as making libraries or databases of the results of their experiments. This
content or related service may help researchers see the big picture faster at
lower cost.
This research report is designed for people that include marketers, business
development, top executives, investors, VCs, consultants, R&D managers,
entrepreneurs and etc. Detailed tables or figures provide key data about items
such as strategic alliances, M&As, market size, segments and the like. This
report includes 21 company profiles that provide the reader a snapshot of the
companiesO focus or activities.
Table of Contents
1. US RNAi Market & Business Models
- 1.1 Overview of RNA Interference
- 1.1.2 Double Stranded RNA (dsRNA)
- 1.1.3 Short interfering RNA; Small interfering RNA (siRNA)
- 1.1.4 Short Hairpin RNA (shRNA)
- 1.1.5 DNA-directed RNAi (ddRNAi)
- 1.1.6 MicroRNA (miRNA)
- 1.2 Current US RNAi Market & Key Customer Applications
- 1.2.1 The Current US RNAi Market
- 1.2.2 RNAi as a Tool for Conventional Drug Discovery
- 1.2.3 RNAi as a Tool for Conventional Drug Development
- 1.2.4 RNAi as a Tool in Basic Research
- 1.2.5 RNAi as Therapeutics
- 1.3 Competitive Landscape
- 1.3.1 Market Map of Major Players 19
- 1.3.2 Major Players by Focus Segment and Product Strategy
- 1.3.3 Research Finding & Analysis
- 1.3.3.1 Market Leaders
- 1.3.3.2 Future Promised Application, Trend
- 1.3.3.3 Strong Technology: Big Picture
- 1.3.3.4 Best Business Model & Product Development Strategy
2. Alliance and M&A Activities
- 2.1 Analysis of RNAi Alliance and M&A Activities, 2003 to Nov-2005
- 2.2 RNAi Alliances and M&As (2003 to Nov-2005)
- 2.3 Legal: Intellectual Property and Regulatory Approval
- 2.3.1 Intellectual Property
- 2.3.2 Regulatory Approval
- 2.4 Researcher Finding: Companies to Watch for Future R&D
- 2.4.1 RNAi Technology Companies on the Move
- 2.4.2 Big Pharma is Starting to Get Involved in RNAi
3. Market Assessment and Trends
- 3.1 Total US RNA Interference (RNAi) Market Size 2004-2009
- 3.2 US RNAi Market by Segments
- 3.2.1 RNAi Market By Application Segments
- 3.2.1.2 RNAi in Basic Research
- 3.2.1.3 RNAi in Drug Discovery
- 3.2.1.4 RNAi in Drug Development
- 3.2.1.5 RNAi Therapeutics
- 3.2.2 RNAi Application Segment Market Shares, 2005 & 2009
- 3.2.3 RNAi Market By Major Disease Segments
- 3.2.3.1 Cancer
- 3.2.3.2 Infections 54
- 3.2.3.3 Metabolic
- 3.2.3.4 Eye disease
- 3.2.3.5 CNS
- 3.2.3.6 Respiratory
- 3.2.3.7 Inflammation
- 3.2.3.8 Bone Diseases
- 3.2.3.9 Blood Disease
- 3.2.3.10 Cardiovascular
- 3.2.3.11Diagnostics, Skin Conditions and Others
- 3.2.4 Major Disease Segment Market Shares (%), 2005 & 2009
- 3.2.5 RNAi Market By Product Segments
- 3.2.5.1 RNAi Reagents & Related Services
- 3.2.5.2 RNAi Delivery Tools & Devices
- 3.2.5.3 Assay Systems
- 3.2.5.4 Cell Lines & Related
- 3.2.5.5 Discovery Techs, Services & Drugs
- 3.2.5.6 Genomewide RNAi HT/ HC Screening Tools
- 3.2.6 RNAi Product Segment Market Shares (%), 2005 & 2009
- 3.3 Key Trends/ Future Directions
- 3.3.1 Big Pharma Starting to Get Involved in RNAi
- 3.3.2 Advances Made in Dealing With Off-target Effects
- 3.3.3 Little Is Known about microRNA Functionality
- 3.3.4 Direct Delivery of RNAi-based Drugs
- 3.3.5 Systemic Delivery of RNAi Drugs
- 3.3.4 RNAi Future Direction Timeline
4. Activities of RNAi-Based Companies
- 4.1 RNAi in Basic Research (5)
- 4.2 RNAi in Drug Discovery (5)
- 4.3 RNAi Drug Development & Therapeutics (11)
5. Findings and Suggestions
- 5.1 Review of Findings and Key Trends
- 5.1.1 RNAi Technology
- 5.1.2 Competitive Landscape
- 5.1.3 Alliances
- 5.1.4 Patents
- 5.1.5 Market Assessment
- 5.2 Recommendations to Capture Opportunities
- 5.3 Current Status: Products Urgently Needed by RNAi Users in R&D
- 5.4 Future Market Prospects
6. Appendix
- 6.1 RNAi Glossary
- 6.2 Company Contacts
LIST OF TABLES
- Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs
- Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs
- Table 3. Major Players in the RNAi Market
- Table 4. Major Players by Focus Segment and Product Strategy
- Table 5. Summary of RNAi Alliances and M&As, 2003 to Nov-2005
- Table 6. Alliances and M&As, 2005
- Table 7. Alliances and M&As, 2004
- Table 8. Alliances and M&As, 2003
- Table 9. RNAi Related Patent Applications, ' 03-' 05
- Table 10. Key Patents for RNAi Reagents and Drugs
- Table 11. Selected RNAi IP Disputes
- Table 12. RNAi Therapeutics In /(or Near) Clinical Trials
- Table 13. RNAi Technology Companies To Watch for R&D
- Table 14. RNAi Alliances Among Big Pharmas
- Table 15. US RNAi Market Size By Total Revenues ($M), 2004-2009 50
- Table 16. US RNAi Market By Application Segment Revenues ($M), 2004-2009
- Table 17. Application Segment Market Shares (%), 2005 & 2009
- Table 18. RNAi Market By Major Disease Segments, Revenues ($M), 2004-2009
- Table 19. Major Disease Segment Market Shares (%), 2005 & 2009
- Table 20. RNAi Market By Product Segments, Revenues ($M), 2004-2009
- Table 21. Product Segment Market Shares (%), 2005 & 2009
- Table 22. RNAi R&D Unmet Needs - Selected Opportunity Matrix
LIST OF ILLUSTRATIONS
- Figure 1. Timeline for Key RNAi Technology Developments
- Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins
- Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC
- Figure 4. RNAi R&D Market by Major Applications
- Figure 5. RNAi Related Patent Applications, ' 03-' 05
- Figure 6. New Drug Approval Timeline and Roadmap
- Figure 7. US RNAi Market Size By Total Revenues ($M), 2004-2009
- Figure 8. US RNAi Market By Application Segment Revenues ($M), 2004-2009
- Figure 9. RNAi Application Segment Market Shares (%), 2005 & 2009
- Figure 10. RNAi Market By Major Disease Segments, Revenues ($M), 2004-2009
- Figure 11. Major Disease Segment Market Shares (%), 2005 & 2009
- Figure 12. RNAi Market By Product Segments, Revenues ($M), 2004-2009
- Figure 13. Product Segment Market Shares (%), 2005 & 2009
- Figure 14. RNAi Future Direction Timeline 2005-2009
|

|